AlphaCrest Capital Management’s VeriSign VRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-8,064
Closed -$1.4M 1111
2022
Q3
$1.4M Sell
8,064
-1,692
-17% -$313K 0.09% 401
2022
Q2
$1.63M Sell
9,756
-8,530
-47% -$1.56M 0.08% 438
2022
Q1
$4.07M Sell
18,286
-11,896
-39% -$2.59M 0.23% 71
2021
Q4
$7.66M Buy
30,182
+3,248
+12% +$751K 0.28% 47
2021
Q3
$5.52M Buy
26,934
+9,693
+56% +$2.12M 0.29% 44
2021
Q2
$3.93M Buy
17,241
+1,595
+10% +$347K 0.17% 162
2021
Q1
$3.11M Buy
15,646
+4,078
+35% +$801K 0.17% 139
2020
Q4
$2.5M Sell
11,568
-3,217
-22% -$658K 0.21% 105
2020
Q3
$3.03M Buy
14,785
+4,525
+44% +$935K 0.33% 36
2020
Q2
$2.12M Buy
10,260
+8,933
+673% +$1.85M 0.35% 41
2020
Q1
$239K Sell
1,327
-6,176
-82% -$1.21M 0.03% 886
2019
Q4
$1.45M Sell
7,503
-13,522
-64% -$2.54M 0.12% 196
2019
Q3
$3.97M Buy
21,025
+15,386
+273% +$3.16M 0.24% 61
2019
Q2
$1.18M Sell
5,639
-393
-7% -$77.2K 0.1% 324
2019
Q1
$1.09M Buy
6,032
+2,536
+73% +$435K 0.17% 154
2018
Q4
$518K Buy
+3,496
New +$524K 0.15% 233

Other funds holding VRSN

AlphaCrest Capital Management's VRSN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of VeriSign (VRSN) in Q4 2022, closing a stake of 8,064 shares — an estimated $1.4M sold.

AlphaCrest Capital Management first reported a position in VRSN in Q4 2018 and held it in 16 quarters. The position peaked at $7.66M in Q4 2021. 611 funds tracked by Wall St. Rank hold VRSN as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining VeriSign position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 8,064 VeriSign shares in Q4 2022, an estimated $1.4M.
  • AlphaCrest Capital Management first reported a position in VeriSign in Q4 2018 and held it in 16 quarters.
  • AlphaCrest Capital Management's VeriSign position peaked at $7.66M in Q4 2021.
  • 611 funds tracked by Wall St. Rank held VeriSign as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.